menu
    • menu
    [{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ulotaront","moa":"TAAR1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sunovion Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Ulotaront","moa":"TAAR1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0.89000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.89000000000000001,"dosageForm":"Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sunovion Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Sunovion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ulotaront","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Sunovion Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Otsuka Pharmaceutical \/ Sunovion Pharmaceuticals"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Otsuka America Pharmaceutical, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ulotaront","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Otsuka America Pharmaceutical, Inc.","highestDevelopmentStatusID":"9","companyTruncated":"Sunovion Pharmaceuticals \/ Otsuka America Pharmaceutical, Inc."},{"orgOrder":0,"company":"Sumitomo","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ulotaront","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sumitomo \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Ulotaront","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Sumitomo Pharma \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma \/ Otsuka Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals for Ulotaront

    Menu

    Ulotaront

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sumitomo Pharma

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Sumitomo Pharma

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ulotaront

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Otsuka Pharmaceutical

                            Deal Size : $30.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Otsuka and Sumitomo Revise License Agreement

                            Details : Under the license agreement, Otsuka holds exclusive rights to develop, manufacture, and commercialize SEP-363856 (ulotaront), TAAR1 agonist. It is being evaluated with the patient for Schizophrenia.

                            Brand Name : SEP-363856

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 15, 2024

                            Lead Product(s) : Ulotaront

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Otsuka Pharmaceutical

                            Deal Size : $30.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sumitomo

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Sumitomo

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ulotaront

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Otsuka Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 DIAMOND 1 and DIAMOND 2 Clinical Studies Eval...

                            Details : SEP-363856 (ulotaront) is a TAAR1 agonist with 5-HT1A agonist activity, is currently under investigation for the treatment of schizophrenia, generalized anxiety disorder and the adjunctive treatment of MDD with additional indications under consideration.

                            Brand Name : SEP-363856

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 31, 2023

                            Lead Product(s) : Ulotaront

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Otsuka Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sunovion Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Sunovion Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ulotaront

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Otsuka America Pharmaceutical, Inc.

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sunovion and Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disord...

                            Details : SEP-363856 (ulotaront) is a TAAR1 agonist with 5-HT1A agonist activity, is currently under investigation for the treatment of schizophrenia, generalized anxiety disorder and the adjunctive treatment of MDD with additional indications under consideration.

                            Brand Name : SEP-363856

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 26, 2023

                            Lead Product(s) : Ulotaront

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Otsuka America Pharmaceutical, Inc.

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Otsuka Pharmaceutical

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Otsuka Pharmaceutical

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ulotaront

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Sunovion Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Otsuka and Sunovion Initiate Clinical Development of Ulotaront for the Adjunctive Treatment of Major Depressiv...

                            Details : Ulotaront (SEP-363856), a TAAR1 agonist with 5-HT1A agonist activity, is currently under investigation for the treatment of schizophrenia as well as the adjunctive treatment of MDD, with additional indications under consideration.

                            Brand Name : SEP-363856

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 01, 2022

                            Lead Product(s) : Ulotaront

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Sunovion Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sunovion Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Sunovion Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ulotaront

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Otsuka Pharmaceutical

                            Deal Size : $890.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Sunovion, Sumitomo Dainippon Pharma and Otsuka Enter Worldwide Development and Commercialization Collaboration

                            Details : The collaboration will focus on solutions to address areas of unmet medical need by advancing four promising compounds―ulotaront (SEP-363856), SEP-4199, SEP-378614 and SEP-380135―that address serious neuropsychiatric disorders.

                            Brand Name : SEP-363856

                            Molecule Type : Small molecule

                            Upfront Cash : $270.0 million

                            September 30, 2021

                            Lead Product(s) : Ulotaront

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Otsuka Pharmaceutical

                            Deal Size : $890.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sunovion Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Sunovion Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ulotaront

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New England Journal of Medicine Publishes Pivotal Results Evaluating Sunovion’s SEP-363856 for the Treatment...

                            Details : Significantly greater improvement in the Positive and Negative Symptom Scale was demonstrated in schizophrenia patients treated with SEP-363856, a TAAR1 agonist, compared to placebo.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 15, 2020

                            Lead Product(s) : Ulotaront

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth